|
|
 |
|
Viewing report
|
|
|
|
Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market
Fuji-Keizai USA, Inc, Dec 2011, Pages: 173
This report reviews and analyzes the big healthcare companies that are entering the field of stem cells in regenerative medicine and stem cells in drug discovery. The research report uses the case study format to benchmark the biggest pharmaceutical or life science tools companies that have entered the stem cell market.
The Big Pharma companies are working with the stem cells in regenerative medicine to develop new cell therapies to will help grow their future pipelines. The report reviews what new stem cell based therapies might become available. The drug makers have also become interested in the potential opportunity to improve their chances for making safer future drugs by using pluripotent stem cells, such as human embryonic stem cells (hESCs) or induced pluripotent stemcells (iPSCs), as well as various kinds of adult stem cells to make customized, disease focused cells used in cell screening campaigns in drug discovery toxicity or efficacy testing. The customized human stem cell-derived cells would eliminate the need to sacrifice millions of lab animals that are currently used in drug safety testing.
The study uncovers interesting information about major life science research tools companies working in the stem cell field that supply key products and services to pharma and academic life science researchers working in stem cell R&D. The report reviews the sources of government and private stem cell research investment. Research and development work in all forms of stem cells is underway at universities, government labs, institutes, cancer centers, hospitals and at drug makers or cell therapeutics companies.
This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. More than 16 detailed tables or figures provide key data about items such as clinical trials, M&As, disease demographics and the like. This report includes seven benchmarking case studies and thirty-eight company profiles that provide the reader with a snapshot of the companies’ focus or activities. The provided Internet links help readers access companies’ own websites for further review.
Benchmarking Analysis Case of Big Companies Entering the Market
Common Research Items:
- Stem Cell Program/Group Overview
- Strategic Focus for Stem Cell Innovations
- Major Corp. Deals, Investment, M&A, etc.
- Stem Cell Related Product Pipeline
- Stem Cell Related R&D
R&D Organization
Research Network including R&D Centers
Budget
Number of Researchers
Target R&D Domain and Noteworthy Area
Developing Technologies
R&D to Commercialization Roadmap
- Analyst’s Comment
|
|
|
|
